Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Tango Therapeutics, Inc.
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06810544CT.gov Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss | — | Recruiting | — | — | — |
NCT05386108CT.gov Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer | — | Recruiting | — | — | — |
NCT04074785CT.gov Abemaciclib w/Bevacizumab in Recurrent GBM Pts w/Loss of CDKN2A/B or Gain or Amplification of CDK4/6 | — | Terminated | — | — | — |
NCT03220646CT.gov Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors | — | Active Not Recruiting | — | — | — |
NCT02644460CT.gov Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Brain Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Abemaciclib (this asset) | Tango Therapeutics, Inc. | P2 | BB · 64 |
| Cediranib | M.D. Anderson Cancer Center | P2 | BBB |
| Temsirolimus | M.D. Anderson Cancer Center | P2 | BBB |
| Sorafenib | National Cancer Institute (NCI) | P2 | BB |
| Dexmedetomidine | Kaohsiung Medical University Chung-Ho Memorial Hospital | P4 | BB |
| Vorinostat | H. Lee Moffitt Cancer Center and Research Institute | P2 | BB |
| Nivolumab | InSightec | P3 | BB |
| Cyclophosphamide | Essen Biotech | P3 | BB |
| Nogitecan | Jeffrey N. Bruce | P2 | BB |
+41 more in the Brain Neoplasm cohort
Other indications for Abemaciclib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hormone Receptor-Positive Breast Cancer | — | P4 | BBB · 72 |
| Estrogen-Receptor Positive Breast Cancer | — | P3 | BB · 70 |
| Metastatic Neoplasm | — | P4 | BB · 67 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Abemaciclib in Brain Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/abemaciclib-brain-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →